| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.965450 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20260924140518 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 250826s2025 onca os f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 041 | 0 |aeng|afre |
|---|
| 043 | |an-cn--- |
|---|
| 045 | |ay1y2 |
|---|
| 086 | 1 |aH82-64/2025-PDF |
|---|
| 100 | 1 |aZhang, Yvonne, |eauthor. |
|---|
| 245 | 10|aCanada's evolving market for biosimilars and what it means for payers = |bL'évolution du marché des biosimilaires au Canada et ce qu'elle signifie pour les payeurs / |cYvonne Zhang. |
|---|
| 246 | 11|aÉvolution du marché des biosimilaires au Canada et ce qu'elle signifie pour les payeurs |
|---|
| 264 | 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2025] |
|---|
| 300 | |a1 online resource (1 page) : |bcolour illustrations |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |a"NPDUIS, National Prescription Drug Utilization Information System." |
|---|
| 520 | |a"Potential savings from biosimilars are a topic of international interest with particular relevance for Canada. Given its high-use and high-price market for biologics, increased biosimilar adoption offers a significant opportunity for cost savings for Canadian payers. Biosimilar switching policies are expected to accelerate cost reductions for biologics in Canada, helping to offset the pressure from new higher-cost medicines. This analysis aims to identify opportunities in the Canadian biosimilar market in comparison with international practices"--Objective. |
|---|
| 546 | |aText in English and French. |
|---|
| 650 | 0|aBiosimilars|zCanada|vStatistics. |
|---|
| 650 | 0|aBiologicals|zCanada|vStatistics. |
|---|
| 650 | 0|aPharmaceutical industry|zCanada|vStatistics. |
|---|
| 655 | 7|aStatistics|2lcgft |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
|---|
| 788 | |tCanada's evolving market for biosimilars and what it means for payers = |efre|w(CaOODSP)9.966233 |
|---|
| 856 | 40|qPDF|s791 KB|uhttps://publications.gc.ca/collections/collection_2026/cepmb-pmprb/H82-64-2025.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/biosimilars-2025poster.html |
|---|